S. Guiu, S. Taillibert, O. Chinot, L. Taillandier, J. Honnorat et al., Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study], Rev Neurol (Paris), vol.164, pp.6-7588, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00476651

M. Wrensch, Y. Minn, T. Chew, M. Bondy, and M. Berger, Epidemiology of primary brain tumors: Current concepts and review of the literature, Neuro-Oncology, vol.4, issue.4, pp.278-99, 2002.
DOI : 10.1215/15228517-4-4-278

M. Tate and M. Aghi, Biology of angiogenesis and invasion in glioma, Neurotherapeutics, vol.2, issue.3, pp.447-57, 2009.
DOI : 10.1016/j.nurt.2009.04.001

. Trial-of-irinotecan, CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study, Neuro Oncol, vol.8, issue.2, pp.189-93, 2006.

R. Zuniga, R. Torcuator, R. Jain, J. Anderson, T. Doyle et al., Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan, 8. stark-vance. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma, pp.329-365, 2009.
DOI : 10.1007/s11060-008-9718-y

J. Vredenburgh, A. Desjardins, J. Herndon, J. Dowell, D. Reardon et al., Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Bevacizumab plus irinotecan in recurrent glioblastoma multiforme, Clin Cancer Res J Clin Oncol, vol.1325, issue.1030, pp.1253-94722, 2007.

D. Macdonald, T. Cascino, S. Schold, J. Cairncross, J. Knopp et al., Response criteria for phase II studies of supratentorial malignant glioma Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging, J Clin Oncol Radiology, vol.8211, issue.123, pp.1277-80791, 1990.

S. Wetzel, S. Cha, G. Johnson, P. Lee, M. Law et al., Relative Cerebral Blood Volume Measurements in Intracranial Mass Lesions: Interobserver and Intraobserver Reproducibility Study, Radiology, vol.224, issue.3, pp.797-803, 2002.
DOI : 10.1148/radiol.2243011014

E. Gerstner, A. Sorensen, R. Jain, T. Batchelor, P. Metellus et al., Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomasValue of relative cerebral blood volume measurement using perfusion MRI in glioma management], Curr Opin Neurol Neurochirurgie, vol.2154, issue.154, pp.728-35503, 2008.

L. Bas, J. Kremer, S. Grand, S. , R. C. et al., NMR perfusion imaging: applications to the study of brain tumor angiogenesis], Bull Acad Natl Med, vol.184, issue.3, pp.557-67, 2000.

L. Bas, J. Grand, S. Kremer, S. Tropres, I. Jiang et al., Place de l???imagerie de perfusion par irm dans la prise en charge des tumeurs c??r??brales, gliales en particulier, Neurochirurgie, vol.51, issue.3-4, pp.287-98, 2005.
DOI : 10.1016/S0028-3770(05)83490-3

L. Bas, J. Paulson, E. Schmainda, and K. , Is perfusion imaging useful for the characterization of brain tumors?] Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors, J Neuroradiol Radiology, vol.34249, issue.192, pp.287-9601, 2007.

A. Lucio-eterovic, Y. Piao, J. De-groot, A. Norden, J. Drappatz et al., Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy Novel anti-angiogenic therapies for malignant gliomas, Clin Cancer Res Lancet Neurol, vol.157, issue.22, pp.4589-991152, 2008.

J. Forsythe, B. Jiang, N. Iyer, F. Agani, S. Leung et al., Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1., Molecular and Cellular Biology, vol.16, issue.9, pp.4604-4617, 1996.
DOI : 10.1128/MCB.16.9.4604

R. Galli, E. Binda, U. Orfanelli, B. Cipelletti, A. Gritti et al., Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma, Cancer Research, vol.64, issue.19, pp.7011-7032, 2004.
DOI : 10.1158/0008-5472.CAN-04-1364

P. Kunkel, U. Ulbricht, P. Bohlen, M. Brockmann, R. Fillbrandt et al., Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2 Invasion as limitation to anti-angiogenic glioma therapy Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis, Cancer Res Acta Neurochir Suppl Leenders WP, Kusters B, de Waal RM Endothelium, vol.61889, issue.272, pp.6624-6632, 2001.

/. Bevacizumab and . Irinotecan, An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study], Rev Neurol (Paris), vol.164, pp.6-7588, 2008.

O. Chinot, New place of the chemotherapy in gliomas], Bull Cancer, vol.92, issue.4, pp.343-54, 2005.

D. Psimaras and J. Delattre, [Perspectives in diagnosis and management of malignant gliomas], Cancer Radiother, vol.12, pp.6-7695, 2008.

M. Wrensch, Y. Minn, T. Chew, M. Bondy, and M. Berger, Epidemiology of primary brain tumors: Current concepts and review of the literature, Neuro-Oncology, vol.4, issue.4, pp.278-99, 2002.
DOI : 10.1215/15228517-4-4-278

. Radiotherapy, WHO Classification of Tumours of the Central Nervous System, N Engl J Med, vol.352, issue.6, pp.987-96, 2005.

M. Mittler, B. Walters, and E. Stopa, Observer reliability in histological grading of astrocytoma stereotactic biopsies, Journal of Neurosurgery, vol.85, issue.6, pp.1091-1095, 1996.
DOI : 10.3171/jns.1996.85.6.1091

D. Figarella-branger, C. Colin, B. Coulibaly, B. Quilichini, M. De-paula et al., Histological and molecular classification of gliomas], Rev Neurol (Paris), vol.164, pp.6-7505, 2008.

D. Parsons, S. Jones, X. Zhang, J. Lin, R. Leary et al., An integrated genomic analysis of human glioblastoma multiforme A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma, Cancer Res Science Cancer Res, vol.6432166, issue.1220, pp.6892-91807, 2004.

J. Jeuken, A. Von-deimling, and P. Wesseling, Molecular pathogenesis of oligodendroglial tumors, Journal of Neuro-Oncology, vol.62, issue.2, pp.161-81, 2004.
DOI : 10.1007/s11060-004-2748-1

W. Mueller, C. Hartmann, A. Hoffmann, W. Lanksch, J. Kiwit et al., Genetic Signature of Oligoastrocytomas Correlates with Tumor Location and Denotes Distinct Molecular Subsets, The American Journal of Pathology, vol.161, issue.1, pp.313-322, 2002.
DOI : 10.1016/S0002-9440(10)64183-1

A. Kanner, S. Staugaitis, E. Castilla, O. Chernova, R. Prayson et al., Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making, J Natl Cancer Inst J Neurosurg, vol.90104, issue.164, pp.1473-9542, 1998.

S. Bao, Q. Wu, R. Mclendon, Y. Hao, Q. Shi et al., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature, vol.8, issue.7120, pp.756-60, 2006.
DOI : 10.1038/nature05236

S. Bao, Q. Wu, S. Sathornsumetee, Y. Hao, Z. Li et al., Stem Cell-like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor, Cancer Research, vol.66, issue.16, pp.7843-7851, 2006.
DOI : 10.1158/0008-5472.CAN-06-1010

G. Liu, X. Yuan, Z. Zeng, P. Tunici, H. Ng et al., Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma Placebocontrolled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group Correlation of O6- methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity, Mol Cancer Lancet J Clin Oncol, vol.534526, issue.2125, pp.671008-124189, 1995.

D. Zagzag, R. Amirnovin, M. Greco, H. Yee, J. Holash et al., Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis, J Clin Oncol Lab Invest, vol.2480, issue.236, pp.2707-14837, 2000.

M. Wong, A. Prawira, A. Kaye, and C. Hovens, Tumour angiogenesis: Its mechanism and therapeutic implications in malignant gliomas, Journal of Clinical Neuroscience, vol.16, issue.9, pp.1119-1149, 2009.
DOI : 10.1016/j.jocn.2009.02.009

. Trial-of-irinotecan, CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study, Neuro Oncol, vol.8, issue.2, pp.189-93, 2006.

R. Zuniga, R. Torcuator, R. Jain, J. Anderson, T. Doyle et al., Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Bevacizumab plus irinotecan in recurrent glioblastoma multiforme, 30. stark-vance. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma, pp.329-361253, 2007.

D. Macdonald, T. Cascino, S. Schold, J. Cairncross, and J. , Response criteria for phase II studies of supratentorial malignant glioma., Journal of Clinical Oncology, vol.8, issue.7, pp.1277-80, 1990.
DOI : 10.1200/JCO.1990.8.7.1277

L. Bas, J. Grand, S. Kremer, S. Tropres, I. Jiang et al., Perfusion MR imaging for initial diagnosis and follow-up of brain tumors]MR and CT perfusion imaging of the brain: principles and clinical applications] Pt 2):444-71. 35. Sorensen. Cerebral MR perfusion imaging. Priciples and current applications Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrastenhanced perfusion MR imaging with glioma grade, -4 Pt 2):287-98. 34. Grand S, pp.746-55, 2000.

H. Aronen, J. Perkio, S. Cha, G. Johnson, A. Mazumdar et al., Dynamic susceptibility contrast MRI of gliomas Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging, Neuroimaging Clin N Am Radiology, vol.12211, issue.43, pp.501-23791, 1999.

S. Wetzel, S. Cha, G. Johnson, P. Lee, M. Law et al., Relative Cerebral Blood Volume Measurements in Intracranial Mass Lesions: Interobserver and Intraobserver Reproducibility Study, Radiology, vol.224, issue.3, pp.797-803, 2002.
DOI : 10.1148/radiol.2243011014

E. Gerstner, A. Sorensen, R. Jain, T. Batchelor, G. Dutertre et al., Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomasValue of relative cerebral blood volume measurement using perfusion MRI in glioma management], Curr Opin Neurol Neurochirurgie, vol.2154, issue.64, pp.728-35503, 2008.

L. Bas, J. Kremer, S. Grand, S. , R. C. et al., NMR perfusion imaging: applications to the study of brain tumor angiogenesis], Bull Acad Natl Med, vol.184, issue.3, pp.557-67, 2000.

L. Bas, J. Paulson, E. Schmainda, and K. , Is perfusion imaging useful for the characterization of brain tumors?] Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors, J Neuroradiol Radiology, vol.34249, issue.442, pp.287-9601, 2007.

R. Weisskoff, C. Zuo, J. Boxerman, B. Rosen, S. Grimault et al., Microscopic susceptibility variation and transverse relaxation: theory and experiment Vessel size imaging, Magn Reson Med Magn Reson Med, vol.3145, issue.63, pp.397-408, 1994.

L. Bas, J. Grand, S. Krainik, A. Lefournier, V. Tropres et al., [Perfusion MR imaging in brain tumors]Advances in adults' gliomas biology, imaging and treatment], J Radiol Pt Bull Cancer, vol.8797, issue.481, pp.807-2117, 2006.

X. Golay, J. Hendrikse, and T. Lim, Perfusion Imaging Using Arterial Spin Labeling, Topics in Magnetic Resonance Imaging, vol.15, issue.1, pp.10-27, 2004.
DOI : 10.1097/00002142-200402000-00003

L. Huwart, N. Michoux, V. Beers, B. Taillandier, L. Antoine et al., Magnetic resonance imaging of angiogenesis in tumors]Cerebral gliomas: imaging diagnosis and follow-up], J Radiol J Radiol, vol.8887, issue.36 2, pp.779-91, 2006.

M. Lev, Y. Ozsunar, J. Henson, A. Rasheed, G. Barest et al., Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected], AJNR Am J Neuroradiol, vol.25, issue.2, pp.214-235, 2004.